Merck & Co., Inc. (NYSE: MRK) has faced pressure over the past year, with shares down about 16% to around $88/share. Slower growth in oncology and vaccine sales has weighed on sentiment, while investors remain cautious about future patent risks for its blockbuster drug, Keytruda. Even so, analysts still view Merck as a steady compounder supported by durable cash flow and strong margins.
Recently, Merck reported solid progress in expanding Keytruda’s use across new cancer indications and shared encouraging trial data for its next-generation cardiovascular drug, sotatercept, which could become a major growth driver by 2026. The company also advanced its vaccine portfolio with new partnerships aimed at scaling global distribution. These developments highlight that Merck is not standing still; it is actively building the next wave of products to offset long-term revenue risks.
This article explores where Wall Street analysts expect Merck’s stock to trade by 2027. We have gathered consensus targets and valuation models to outline the stock’s potential path. These figures reflect current analyst expectations and are not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
Merck trades at about $88/share today. The average analyst price target is $102/share, which points to roughly 17% upside. Forecasts show a fairly tight range, suggesting moderate conviction among analysts:
- High estimate: ~$137/share
- Low estimate: ~$82/share
- Median target: ~$98/share
- Ratings: 13 Buys, 13 Holds, 2 Outperforms
For investors, this outlook signals cautious optimism. Merck is seen as a reliable income and compounding play, with limited downside and steady upside potential if its pipeline execution stays on track.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
Merck: Growth Outlook and Valuation
Merck’s fundamentals appear steady, supported by strong margins and disciplined cost management:
- Revenue is expected to grow about 3–4% annually through 2027
- Operating margins are projected near 42%
- Shares trade around 9.7x forward earnings, slightly below long-term averages
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 9.7x forward P/E suggests ~$111/share by 2027
- That implies about 28% total upside, or roughly 12% annualized returns
For investors, the takeaway is clear. Merck offers a balanced setup where valuation looks reasonable, profitability remains strong, and dividends provide consistent returns while investors wait for the next leg of growth.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
Merck’s leadership in oncology continues to anchor its long-term story. Keytruda remains a global growth engine, expanding into new indications that extend its patent runway and revenue base. Beyond oncology, progress in cardiovascular treatments like sotatercept and steady vaccine momentum help diversify earnings sources.
Management’s focus on cost efficiency, pipeline innovation, and global expansion provides a solid foundation for consistent cash generation. For investors, these strengths show Merck is evolving beyond a single-drug story and positioning itself for sustainable growth through 2027.
Bear Case: Patent Risk and Growth Slowdown
Even with these positives, Merck faces an inevitable patent cliff as Keytruda’s exclusivity winds down later this decade. Any delays in new product approvals could leave a near-term earnings gap once that protection fades.
Competition in oncology and vaccines is also intensifying, which could pressure margins if Merck has to cut prices to maintain share. For investors, the main risk is execution. If Merck cannot replace Keytruda’s revenue base quickly enough, growth could flatten, limiting future stock performance.
Outlook for 2027: What Could Merck Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 9.7x forward P/E suggests Merck could trade near $111/share by 2027. That would represent about 28% total upside from current levels, or roughly 12% annualized returns.
This forecast assumes steady earnings growth, improving margins, and continued shareholder returns through dividends and buybacks. While not a high-growth story, Merck’s predictable cash flow and healthy balance sheet make it appealing for long-term investors seeking stable, compounding returns rather than speculative gains.
For investors, Merck looks like a durable healthcare compounder that rewards patience with reliable income and steady capital appreciation over time.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Click here to sign up for TIKR and get your free copy of TIKR’s 5 AI Compounders report today.
